Cat. No. | Product name | CAS No. |
DC23019 |
PACMA 31
Featured
An orally active, irreversible inhibitor of protein disulfide isomerase (PDI), forming a covalent bond with the active site cysteines of PDI. |
1401089-31-3 |
DC21242 |
LM11A-31 dihydrochloride
Featured
An orally available, brain penetrant p75NTR ligand that blocks p75-mediated cell death, also increases proliferation and survival of hippocampal neural progenitors. |
1243259-19-9 |
DC24008 |
Eperezolid
Featured
An oxazolidinone antibiotic that possesses potent antimicrobial activity in vitro and in vivo.. |
165800-04-4 |
DC20418 |
InS3-54
Featured
An STAT3 inhibitor that selectively targets the DNA-binding domain of STAT3, without affecting the activation and dimerization of STAT3. |
328998-92-1 |
DC7815 |
Crisaborole(AN-2728)
Featured
AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines. |
906673-24-3 |
DC9827 |
AN3365(Epetraborole)
Featured
AN3365 is a first-in-class antibiotic that demonstrates potent activity across a wide spectrum of Gram-negative bacteria, including those resistant to many other antibiotics. |
1234563-16-6 |
DC8029 |
ANA-12
Featured
ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice. |
219766-25-3 |
DC8322 |
Anacardic Acid
Featured
Anacardic acid inhibits the histone acetyltransferase (HAT) activity of the transcription co-activators p300 and p300/CREB-binding protein-associated factor (pCAF) with IC50 values of 8.5 and 5 µM, respectively. |
16611-84-0 |
DC7804 |
Anacetrapib(MK0859)
Featured
Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
875446-37-0 |
DC7357 |
Anamorelin
Featured
Anamorelin(RC1291; ONO-7643) is a synthetic orally active ghrelin receptor agonist which is under development for the management of non-small lung cancer associated cachexia/anorexia. |
249921-19-5 |
DCAPI1425 |
Anastrozole
Featured
Anastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition. |
120511-73-1 |
DC11649 |
Jamaicin (AnCoA4)
Featured
AnCoA4 (AnCoA-4, AnCoA 4) is a potent Orai1 channel inhibitor that inhibits store-operated calcium (SOC) with EC50 of 0.88 uM. |
24211-36-7 |
DC8122 |
Andarine (GTX-007,S-4)
Featured
Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist. |
401900-40-1 |
DCAPI1490 |
Anidulafungin
Featured
Anidulafungin |
166663-25-8 |
DC10168 |
Anle138b
Featured
Anle138b is a novel oligomer modulator. |
882697-00-9 |
DC8802 |
Maytansinol(Ansamitocin P-0)
Featured
Maytansinol inhibits microtubule assembly and induces microtubule disassembly in vitro. Target: Microtubule/Tubulin in vitro: Maytansinol disrupts the mitotic spindle and prevents mitotic exit in Drosophila. Maytansinol reduces the growth and/or survival of HCT116 cells in a dose-dependent manner and that the effect was more severe for p53+/+ than for p53-/- cells at both low and high doses. Maytansinol inhibits the growth of HCT116 human colon cancer cells. Maytansinol induces apoptosis in imaginal discs of wild-type larvae but not p53 mutant larvae. This parallels the finding in human HCT116 cells, in which Maytansinol was more effective when p53 was present, at least at some doses. Maytansinol induces apoptosis in imaginal discs of wild-type larvae but not p53 mutant larvae at 24 hours after exposure to drug. |
57103-68-1 |
DC8241 |
Ansamitocin P-3
Featured
Ansamitocin P-3, a potent anti-tumor maytansinoid found in Actinosynnema pretiosum, is a maytansine analog which displays potent cytotoxicity against the human solid tumor cell lines A-549 and HT-29. |
66584-72-3 |
DC20670 |
ANT431
Featured
ANT431 is a novel potent metallo-β-lactamase (MBL) inhibitor with IC50 of 290 nM and 195 nM for NDM-1 and VIM-2, shows a comparatively weak inhibitor of VIM-1 and IMP-1 (Ki of 14.6 and 4.15 uM, respectively). |
1639972-90-9 |
DC20078 |
AP1867
Featured
AP1867 is a synthetic FKBP12F36V-directed ligand. |
195514-23-9 |
DC22207 |
AP1903
Featured
AP1903 (Rimiducid, AP-1903) is a potent, specific synthetic ligand of FKBP Phe36Val mutant (F36V-FKBP) with binding IC50 of 1.8 nM. |
195514-63-7 |
DC1020 |
Ponatinib (AP24534)
Featured
AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. |
943319-70-8 |
DC5198 |
ALK-IN-1 (Brigatinib analog)
Featured
ALK-IN-1 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. |
1197958-12-5 |